The drug delivery market offers diverse product types tailored for optimal therapeutic outcomes. Oral drug delivery ensures patient-friendly ingestion, while pulmonary delivery targets respiratory conditions. Injectable drug delivery provides precise administration, and ophthalmic delivery addresses ocular disorders. Nasal and topical delivery offer alternative routes, and implantable delivery provides sustained release. Transmucosal delivery caters to mucosal absorption. This array of delivery methods reflects the industry's commitment to enhancing efficacy, patient compliance, and therapeutic precision across various medical applications.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-drug-delivery-market
Data Bridge Market Research analyses that the Global Drug Delivery Market was valued at USD 1,458.19 million in 2021 and is expected to reach USD 2,800.61 million by 2029, registering a CAGR of 8.50% during the forecast period of 2022 to 2029. The increasing prevalence of chronic diseases underscores the need for advanced drug delivery mechanisms. Tailored and targeted delivery systems are crucial in ensuring the effectiveness of treatments, optimizing therapeutic outcomes, and improving the overall management of chronic conditions for patients worldwide.
Key Findings of the Study
The expanding geriatric population is expected to drive the market's growth rate
The expanding geriatric population globally heightens the demand for sophisticated drug administration solutions. With aging, the need for efficient and patient-friendly drug delivery becomes imperative. Tailored systems that accommodate the unique needs of the elderly contribute to improved adherence and overall healthcare outcomes. This demographic shift emphasizes the importance of developing and implementing innovative drug delivery technologies to address the specific challenges associated with medication management in the elderly, enhancing their overall quality of life.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), Application (Cancer, Diabetes, Respiratory Diseases, Cardiovascular Diseases, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bausch Health Companies Inc. (Canada), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), Cadila Pharmaceuticals. (India), Dr. Reddy's Laboratories Ltd. (India), 3M (U.S.), Bayer AG (Germany), Astellas Pharma Inc. (Japan), AbbVie Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global drug delivery market is segmented on the basis of product type, application, end-users, and distribution channel.
- On the basis of product type, the global drug delivery market is segmented into oral drug delivery, pulmonary drug delivery, injectable drug delivery, ophthalmic drug delivery, nasal drug delivery, topical drug delivery, implantable drug delivery, and transmucosal drug delivery
- On the basis of application, the global drug delivery market is segmented into cancer, diabetes, respiratory diseases, cardiovascular diseases, and others
- On the basis of end-users, the global drug delivery market is segmented into hospitals, specialty clinics, homecare, and others
- On the basis of distribution channel, the global drug delivery market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others
Major Players
Data Bridge Market Research recognizes the following companies as the global drug delivery market players in global drug delivery market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.).
Market Developments
- In June 2022, Gufic Biosciences Ltd introduced a groundbreaking drug delivery system, Dual Chamber Bags, in India, offering affordability. This innovation marks a significant milestone in healthcare accessibility by providing cost-effective solutions. The Dual Chamber Bags represent a commitment to expanding patient access to advanced drug delivery methods, addressing healthcare needs, and contributing to the broader landscape of pharmaceutical advancements in the Indian market
- In March 2022, Sandoz, a division of Novartis, completed the acquisition of Coalesce Product Development Limited, a UK-based medical and drug delivery device company. This strategic move enhances Sandoz's respiratory medication portfolio by incorporating Coalesce's expertise and assets. The acquisition positions Sandoz to advance its capabilities in delivering high-quality, complex therapeutics, ultimately improving patient access to innovative respiratory treatments and strengthening its presence in the healthcare market
- In February 2022, Takeda achieved US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). This advancement is a significant development in the management of hereditary angioedema (HAE) for both adult and pediatric patients aged 12 and above. The approval enhances treatment accessibility, offering a convenient and effective solution for preventing HAE attacks and improving overall patient care
Regional Analysis
Geographically, the countries covered in the global drug delivery market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global drug delivery market during the forecast period 2022-2029
North America dominates the drug delivery market due to major industry players and robust healthcare infrastructure. The region's dominance is accentuated by a rising incidence of chronic diseases and ongoing developments in biologics, pharmaceutical drugs, and innovative delivery devices. These factors collectively contribute to a sustained growth trajectory, positioning North America as a key hub for advancements and market expansion in the dynamic field of drug delivery.
Asia-Pacific is expected to dominate the global drug delivery market in the forecast period 2022-2029
The Asia-Pacific is expected to dominate the drug delivery market due to the rising geriatric demographic and the accessibility of self-administration options. The region's expanding healthcare infrastructure adds momentum to this trajectory, fostering increased adoption of advanced drug delivery systems. These factors collectively contribute to the region's promising market outlook, emphasizing the significance of evolving healthcare dynamics and demographic shifts in shaping the pharmaceutical landscape in Asia-Pacific.
For more detailed information about the global drug delivery market report, click here – https://www.databridgemarketresearch.com/reports/global-drug-delivery-market
